Global X Japan Co. Ltd. Acquires 4,369 Shares of McKesson Corporation $MCK

Global X Japan Co. Ltd. increased its holdings in shares of McKesson Corporation (NYSE:MCK) by 423.4% during the fourth quarter, HoldingsChannel reports. The firm owned 5,401 shares of the company’s stock after buying an additional 4,369 shares during the period. Global X Japan Co. Ltd.’s holdings in McKesson were worth $4,430,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently made changes to their positions in the stock. J.W. Cole Advisors Inc. grew its stake in shares of McKesson by 35.3% during the 3rd quarter. J.W. Cole Advisors Inc. now owns 5,089 shares of the company’s stock valued at $3,931,000 after purchasing an additional 1,329 shares during the period. Private Wealth Partners LLC increased its stake in shares of McKesson by 5.6% in the third quarter. Private Wealth Partners LLC now owns 31,841 shares of the company’s stock worth $24,598,000 after purchasing an additional 1,682 shares in the last quarter. AlphaQuest LLC raised its holdings in McKesson by 91.2% during the third quarter. AlphaQuest LLC now owns 1,767 shares of the company’s stock valued at $1,365,000 after acquiring an additional 843 shares during the period. CW Advisors LLC lifted its position in shares of McKesson by 282.5% in the second quarter. CW Advisors LLC now owns 11,008 shares of the company’s stock valued at $8,067,000 after acquiring an additional 8,130 shares in the last quarter. Finally, Envestnet Asset Management Inc. boosted its stake in shares of McKesson by 12.4% in the third quarter. Envestnet Asset Management Inc. now owns 330,647 shares of the company’s stock worth $255,438,000 after acquiring an additional 36,451 shares during the period. 85.07% of the stock is currently owned by institutional investors.

McKesson Price Performance

McKesson stock opened at $864.43 on Friday. The firm has a 50-day moving average of $907.21 and a two-hundred day moving average of $837.67. McKesson Corporation has a 1 year low of $637.00 and a 1 year high of $999.00. The stock has a market cap of $105.88 billion, a price-to-earnings ratio of 24.86, a price-to-earnings-growth ratio of 1.42 and a beta of 0.38.

McKesson (NYSE:MCK) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $9.34 earnings per share for the quarter, beating analysts’ consensus estimates of $9.19 by $0.15. McKesson had a negative return on equity of 338.97% and a net margin of 1.09%.The company had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. During the same quarter last year, the company earned $8.03 earnings per share. The firm’s revenue for the quarter was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. Research analysts expect that McKesson Corporation will post 32.77 earnings per share for the current year.

McKesson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 1st. Shareholders of record on Monday, March 2nd will be paid a dividend of $0.82 per share. The ex-dividend date is Monday, March 2nd. This represents a $3.28 dividend on an annualized basis and a dividend yield of 0.4%. McKesson’s dividend payout ratio (DPR) is presently 9.43%.

Insiders Place Their Bets

In related news, Director Maria Martinez sold 349 shares of the company’s stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $939.87, for a total transaction of $328,014.63. Following the completion of the sale, the director owned 301 shares of the company’s stock, valued at approximately $282,900.87. This represents a 53.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Thomas L. Rodgers sold 276 shares of the business’s stock in a transaction dated Monday, January 5th. The shares were sold at an average price of $816.18, for a total transaction of $225,265.68. Following the completion of the transaction, the executive vice president owned 2,268 shares in the company, valued at $1,851,096.24. The trade was a 10.85% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 3,868 shares of company stock worth $3,743,820. Corporate insiders own 0.08% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. Evercore reiterated an “outperform” rating on shares of McKesson in a research report on Thursday, March 5th. TD Cowen lifted their price objective on McKesson from $1,000.00 to $1,012.00 and gave the stock a “buy” rating in a research note on Thursday, February 5th. Leerink Partners reaffirmed an “outperform” rating and set a $1,085.00 price objective on shares of McKesson in a report on Thursday, March 5th. Deutsche Bank Aktiengesellschaft reissued a “buy” rating on shares of McKesson in a report on Wednesday, December 10th. Finally, JPMorgan Chase & Co. boosted their price target on shares of McKesson from $983.00 to $1,107.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Thirteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, McKesson currently has a consensus rating of “Moderate Buy” and a consensus target price of $960.93.

McKesson Profile

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.